Advertisement
A live audio webcast of the conference call will be available atwww.novavax.com. Please connect to this website at least 15 minutes prior tothe conference call to ensure adequate time for any software download that maybe needed to hear the webcast. A replay of the webcast will be available for90 days after the webcast and a replay of the conference call will also beavailable by telephone beginning 1pm EDT. August 8, 2008 through midnightAugust 15, 2008. To access the replay, dial (703) 925 2533 and enter pass code1262311.
Advertisement
About Novavax, Inc.
Novavax, Inc. is a clinical stage biotechnology company, creating novelvaccines to address a broad range of infectious diseases worldwide usingadvanced proprietary virus-like particle (VLP) technology. The Companyproduces these VLP based, highly potent, recombinant vaccines utilizing a new,efficient manufacturing solution. Additional information about Novavax isavailable at www.novavax.com and in the company's various filings with theSecurities and Exchange Commission.
Forward Looking Statements
Statements herein relating to future financial or business performance,conditions or strategies and other financial and business matters, includingexpectations regarding future revenues, product safety or efficacy, patentprotection, operating expenses, and clinical developments are forward-lookingstatements within the meaning of the Private Securities Litigation Reform Act.Novavax cautions that these forward-looking statements are subject to numerousassumptions, risks and uncertainties, which change over time. Factors thatmay cause actual results to differ materially from the results discussed inthe forward-looking statements or historical experience include risks anduncertainties, including the failure by Novavax to secure and maintainrelationships with collaborators; risks relating to the early stage ofNovavax's product candidates under development; uncertainties relating toclinical trials; risks relating to the commercialization, if any, of Novavax'sproposed product candidates; dependence on the efforts of third parties;dependence on intellectual property; competition for clinical resources andpatient enrollment from drug candidates in development by other companies withgreater resources and visibility; and risks that we may lack the financialresources and access to capital to fund our operations. Further informationon the factors and risks that could affect Novavax's business, financialconditions and results of operations, is contained in Novavax's filings withthe U.S. Securities and Exchange Commission, which are available atwww.sec.gov. These forward-looking statements speak only as of the date ofthis press release, and Novavax assumes no duty to update forward-lookingstatements.
SOURCE Novavax, Inc.
